Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488306 | 1.00 | XDH (0.54) | XDHLMNAS1PR1S1PR3MAPT | |
| SCHEMBL932740 | 0.88 | XDH (0.54) | XDHS1PR1S1PR3 | |
| SCHEMBL24860790 | 0.87 | MAPT (0.43) | XDHLMNAS1PR1S1PR3MAPT | |
| SCHEMBL8148281 | 0.86 | CA1 (0.52) | XDHLMNAMAPT | |
| SCHEMBL31139622 | 0.85 | MAPT (0.44) | XDHLMNAMAPT | |
| SCHEMBL28956905 | 0.85 | MAPT (0.44) | XDHLMNAMAPT | |
| SCHEMBL30603423 | 0.85 | XDH (0.67) | XDH | |
| SCHEMBL28323507 | 0.85 | XDH (0.56) | XDHS1PR1S1PR3 | |
| SCHEMBL403398 | 0.85 | XDH (0.67) | XDH | |
| SCHEMBL28140004 | 0.85 | ALDH1A1 (0.52) | XDHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4444697-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118632834-A | Indanyl compounds containing carboxylic acids for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-09-10 | — | — | CN | disclosed |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11584726-B2 | Amino alcohol derivative, pharmaceutical composition and application thereof | BEIJING FORELAND PHARMA CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| US-20030036551-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-02-20 | — | — | US | disclosed |
| US-6492388-B1 | SUCH AS N-(5-CHLORO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)-4-ETHOXYBENZAMIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-10 | — | — | US | disclosed |
| US-6492378-B1 | Substituted isoquinoline derivatives and their use as anticonvulsivants | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-10 | — | — | US | disclosed |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM P.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6410555-B1 | ANTIEPILEPTIC AGENTS; HEADACHES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | disclosed |
| US-6245778-B1 | 1,6-naphthyridine anti-convulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-06-12 | — | — | US | disclosed |
| EP-0986559-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-22 | — | — | EP | disclosed |
| EP-0968190-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998054184-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998041508-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | CNR1, SCN1B, CNR2 | XDH 1833/4885LMNA 906/4885S1PR1 1204/4885 |
| US-20030036551-A1 | Novel compounds | SCN1B, CNR1, SCN1A | XDH 2349/4885LMNA 1879/4885S1PR1 1600/4885 |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | AZI2, GABBR2, CNDP2 | XDH 303/4885LMNA 4746/4885S1PR1 379/4885 |
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | XDH 3448/4885LMNA 2537/4885S1PR1 4/4885 |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | AZI2, GABBR2, CNDP2 | XDH 303/4885LMNA 4746/4885S1PR1 379/4885 |
| US-11584726-B2 | Amino alcohol derivative, pharmaceutical composition and application thereof | SSB, HLA-DRB1, LCP2 | XDH 1246/4885LMNA 438/4885S1PR1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.